Infirst's 'ChocoCough' gets £25 million backing
This article was originally published in Scrip
Executive Summary
Infirst Healthcare, a new company led by the former president of GlaxoSmithKline's European consumer healthcare business, has raised £25 million from Invesco Asset Management to launch products into the cough/cold and pain consumer healthcare markets.Infirst was spun out of the privatelyheld UK-based drug discovery group SEEK, which was founded in 2004 and previously known as PepTcell. SEEK and its US partner Pernix Therapeutics had initially hoped to find a partner to move the assets forward (scripintelligence.com, 28 March 2011).